Interestingly, PD-L1 expression was increased not only in CD45+ leukocytes (Supplementary Fig. 1F) but also in CD45− cells (Supplementary Fig. 1E) when comparing wild-type and Nr2f6-deficient B16-OVA tumor-bearing mice on d14 after tumor challenge, suggesting that loss of NR2F6 in T cells overcomes even high expression of these well-known immune-suppressive checkpoint receptors. The gene discussed is NR2F6; the disease is neoplasm.